Shanghai Hongcheng Pharmaceutical Co. Ltd.

Primary objective: To evaluate the tolerability and safety of HC006 combined with PD-1 inhibitors in patients with advanced solid tumors and determine the recommended dose (RD) for subsequent studies Secondary objectives: (1) To evaluate the pharmacokinetic characteristics of HC006 combined with PD-1 inhibitors in patients with advanced solid tumors; (2) To evaluate the immunogenicity of HC006 combined with PD-1 inhibitors in patients with advanced solid tumors; (3) To evaluate the efficacy of HC006 combined with PD-1 inhibitors in patients with advanced solid tumors. Exploratory objectives: (1) To explore the infiltration of CD8+ immune cells in tumor tissues before treatment, as well as the expression levels of CCR8 and PD-L1; if data permit, to explore the infiltration of CD8+ immune cells after treatment, as well as the expression levels of CCR8 and PD-L1; (2) To explore the levels of cytokines in the blood before and after treatment.